cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Annovis Bio
10 own
4 watching
Current Price
$5.65
$-0.08
(-1.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
96.46M
52-Week High
52-Week High
22.49000
52-Week Low
52-Week Low
4.53000
Average Volume
Average Volume
0.28M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization96.46M
icon52-Week High22.49000
icon52-Week Low4.53000
iconAverage Volume0.28M
iconDividend Yield--
iconP/E Ratio--
What does the Annovis Bio do?
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Read More
How much money does Annovis Bio make?
News & Events about Annovis Bio.
Business Wire
1 year ago
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinsons Disease (PD) patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The feedback...
TipRanks Financial Blog
1 year ago
Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS Research Report) yesterday and set a price target of $26.00. The ... Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS Res...
PR Newswire
1 year ago
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION PR Newswire BERWYN, Pa., April 11, 2023 BERWYN, Pa., April 11, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ('Annovis' or the...
PR Newswire
1 year ago
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease PR...
Frequently Asked Questions
Frequently Asked Questions
What is Annovis Bio share price today?
plus_minus_icon
Can Indians buy Annovis Bio shares?
plus_minus_icon
How can I buy Annovis Bio shares from India?
plus_minus_icon
Can Fractional shares of Annovis Bio be purchased?
plus_minus_icon
What are the documents required to start investing in Annovis Bio stocks?
plus_minus_icon
What is today’s traded volume of Annovis Bio?
plus_minus_icon
What is today’s market capitalisation of Annovis Bio?
plus_minus_icon
What is the 52-Week High and Low Range of Annovis Bio?
plus_minus_icon
What percentage is Annovis Bio down from its 52-Week High?
plus_minus_icon
What percentage is Annovis Bio up from its 52-Week Low?
plus_minus_icon
Current Price
$5.65
$-0.08
(-1.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00